An inflammation of the cow's mammary gland, bovine mastitis is typically brought on by a bacterial infection, although it can also be brought on by viruses, fungi, or trauma. It has an impact on milk output and quality, which causes the dairy industry to suffer large financial losses. Mastitis may be subclinical, with no outward symptoms, or clinical, with symptoms that are readily apparent. To preserve udder health and dairy productivity, effective management entails timely treatment, routine screening, and good hygiene.

Drivers: A growing world population and rising disposable incomes are driving up demand for dairy products, which in turn is driving up demand for healthier dairy animals and more efficient milk production. Because of this, the dairy sector places a high premium on managing mastitis effectively. The adoption of preventive and treatment measures is also being aided by dairy farmers' growing knowledge of the negative effects mastitis has on their health and the economy. Additionally, the development of diagnostic instruments like PCR, ELISA, and MALDI-TOF enables precise and prompt identification of microorganisms that cause mastitis.  These developments, when combined with the creation of novel therapeutic alternatives, such as non-antibiotic therapies, are greatly boosting the market for bovine mastitis.

Challenges: Clinical or subclinical mastitis significantly lowers milk yield, which has an effect on a farmer's earnings and the productivity of the dairy industry. Mastitis not only reduces milk's quantity but also degrades its quality by changing its composition, lowering important components like lactose, fat, and casein. This lowers the milk's market value and can make it more difficult to produce cheese efficiently. Dairy operations are also financially burdened by the expenses of treatment, which include veterinary care, antibiotics, and additional labour for caring for and managing ill cows.

Market Trends: Dairy cattle populations are growing as a result of the growing demand for milk and dairy products worldwide, which is being fuelled by changes in eating patterns and population increase. This highlights the importance of managing mastitis effectively. Dairy farmers are consequently become increasingly conscious of the substantial negative effects mastitis has on milk output and herd health and the economy. Increased use of diagnostic instruments and therapeutic approaches is being fuelled by this awareness. Further propelling market expansion are technical developments that are revolutionising mastitis control, such as automated detection systems, precision medicine, and cutting-edge non-antibiotic treatments.

Boehringer, Ceva, Elanco, Forte Healthcare Ltd, Heilsaa, HIPRA, Immucell Corporation, Merck & Co., Inc, Virbac, and Zoetis are just a few of the major market players that are thoroughly examined in this market study along with revenue analysis, market segments, and competitive landscape data.

By Product: Based on the Product, Global Bovine Mastitis Market is segmented as; Pharmaceuticals, Antibiotics, Vaccines, Diagnostics, Others.

By Route of Administration: Based on the Route of Administration, Global Bovine Mastitis Market is segmented as; Intra-Mammary, Systemic.

By Therapy: Based on the Therapy, Global Bovine Mastitis Market is segmented as; Dry Period, Lactating Period.

By Type: Based on the Type, Global Bovine Mastitis Market is segmented as; Clinical Mastitis, Sub-Clinical Mastitis.

By End-User: Based on the End-User, Global Bovine Mastitis Market is segmented as; Veterinary Hospitals/Clinics, Others.

 

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.